<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00121303</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000433422</org_study_id>
    <secondary_id>SAKK-AML-43</secondary_id>
    <secondary_id>EU-20514</secondary_id>
    <secondary_id>HOVON-AML-43</secondary_id>
    <nct_id>NCT00121303</nct_id>
  </id_info>
  <brief_title>Cytarabine and Daunorubicin With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes</brief_title>
  <official_title>Randomised Induction and Post Induction Therapy in Older Patients (≥61 Years of Age) With Acute Myeloid Leukemia (AML) and Refractory Anemia With Excess Blasts (RAEB, RAEB-t)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stichting Hemato-Oncologie voor Volwassenen Nederland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stichting Hemato-Oncologie voor Volwassenen Nederland</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as cytarabine and daunorubicin, work in different&#xD;
      ways to stop the growth of cancer cells, either by killing the cells or by stopping them from&#xD;
      dividing. Monoclonal antibodies, such as gemtuzumab ozogamicin, can block cancer growth in&#xD;
      different ways. Some block the ability of cancer cells to grow and spread. Others find cancer&#xD;
      cells and help kill them or carry cancer-killing substances to them. It is not yet known&#xD;
      whether cytarabine and daunorubicin followed by gemtuzumab ozogamicin is more effective than&#xD;
      cytarabine and daunorubicin in treating acute myeloid leukemia or myelodysplastic syndromes.&#xD;
&#xD;
      PURPOSE: This randomized phase III trial is studying cytarabine and two different doses of&#xD;
      daunorubicin to see how well they work compared to cytarabine and daunorubicin followed by&#xD;
      gemtuzumab ozogamicin in treating older patients with acute myeloid leukemia or&#xD;
      myelodysplastic syndromes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Compare the event-free and disease-free survival of older patients with acute myeloid&#xD;
           leukemia, refractory anemia with excess blasts (RAEB), or RAEB in transformation treated&#xD;
           with induction therapy comprising cytarabine in combination with two different doses of&#xD;
           daunorubicin followed by cytarabine alone with or without post-induction therapy&#xD;
           comprising gemtuzumab ozogamicin.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Compare the complete remission rate in patients treated with these regimens.&#xD;
&#xD;
        -  Compare the overall survival of patients treated with these regimens.&#xD;
&#xD;
        -  Compare the toxicity of these regimens in these patients.&#xD;
&#xD;
        -  Determine the probability of relapse and death during first complete remission in&#xD;
           patients treated with post-induction gemtuzumab ozogamicin.&#xD;
&#xD;
        -  Correlate prognostic factors (e.g., CD33 positivity, multidrug resistance phenotype, or&#xD;
           cytogenetics) with probability of complete remission and overall, event-free, and&#xD;
           disease-free survival of patients treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to&#xD;
      participating center and diagnosis (acute myeloid leukemia [AML] vs myelodysplastic syndromes&#xD;
      [MDS]) for induction therapy. Patients are stratified according to participating center,&#xD;
      diagnosis (AML vs MDS), induction treatment arm (I vs II), and response to induction therapy&#xD;
      (complete remission [CR] vs no CR) for post-induction therapy.&#xD;
&#xD;
        -  Induction therapy (course 1): Patients are randomized to 1 of 2 induction treatment&#xD;
           arms.&#xD;
&#xD;
             -  Arm I: Patients receive cytarabine IV continuously on days 1-7 and daunorubicin IV&#xD;
                over 3 hours on days 1-3.&#xD;
&#xD;
             -  Arm II: Patients receive cytarabine as in arm I and daunorubicin as in arm I but at&#xD;
                a higher dose.&#xD;
&#xD;
      Approximately 28-35 days after the start of course 1 (or sooner if the bone marrow shows&#xD;
      evidence of resistant disease), patients in both arms proceed to course 2 of induction&#xD;
      therapy.&#xD;
&#xD;
        -  Induction therapy (course 2): All patients receive cytarabine IV over 6 hours twice&#xD;
           daily on days 1-6.&#xD;
&#xD;
      After completion of course 2, patients undergo assessment of remission status. Patients who&#xD;
      do not achieve CR are removed from the study. Patients achieving CR proceed to post-induction&#xD;
      therapy and undergo a second randomization.&#xD;
&#xD;
        -  Post-induction therapy: Patients are randomized to 1 of 2 post-induction treatment arms.&#xD;
&#xD;
             -  Arm I: Patients receive no further chemotherapy.&#xD;
&#xD;
             -  Arm II: Patients receive gemtuzumab ozogamicin IV over 2 hours on days 1, 29, and&#xD;
                57 in the absence of disease relapse or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed monthly for 1 year, every 3 months&#xD;
      for 2 years, every 4-6 months for 2 years, and then periodically thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 600 patients will be accrued for this study within 4-5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free survival after induction therapy</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease-free survival after maintenance therapy</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete remission (CR) rate after induction therapy</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival after induction therapy</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity after induction therapy</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity after maintenance therapy</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Probability of relapse and death in first CR after maintenance therapy</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival after maintenance therapy</measure>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>Arm A low dose Dauno</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Induction 45 mg Dauno</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM B high dose Dauno</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction 90 mg Dauno</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 1 no further treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 Mylotarg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Post induction treatment with Mylotarg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
    <arm_group_label>ARM B high dose Dauno</arm_group_label>
    <arm_group_label>Arm A low dose Dauno</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>daunorubicin hydrochloride</intervention_name>
    <arm_group_label>ARM B high dose Dauno</arm_group_label>
    <arm_group_label>Arm A low dose Dauno</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemtuzumab ozogamicin</intervention_name>
    <arm_group_label>Arm 2 Mylotarg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed diagnosis of 1 of the following:&#xD;
&#xD;
               -  Acute myeloid leukemia (AML)&#xD;
&#xD;
                    -  M0-M2 or M4-M7 FAB subtype&#xD;
&#xD;
                         -  No AML with cytogenetic abnormality t(15;17) (M3)&#xD;
&#xD;
                    -  Patients with secondary AML progressing from prior myelodysplasia* or&#xD;
                       biphenotypic leukemia are eligible&#xD;
&#xD;
               -  Refractory anemia with excess blasts (RAEB) or RAEB in transformation&#xD;
&#xD;
                    -  International Prognostic Scoring System score ≥ 1.5 NOTE: *Any prior&#xD;
                       hematological disease of ≥ 4 months duration&#xD;
&#xD;
          -  No chronic myelogenous leukemia in blastic crisis&#xD;
&#xD;
          -  No prior polycythemia rubra vera&#xD;
&#xD;
          -  No primary myelofibrosis&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  61 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  WHO 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  ALT and/or AST ≤ 2.5 times upper limit of normal (ULN)*&#xD;
&#xD;
          -  Bilirubin ≤ 2 times ULN* NOTE: *Unless elevation is caused by organ infiltration by&#xD;
             AML&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 2 times ULN* NOTE: *Unless elevation is caused by organ infiltration by&#xD;
             AML&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  LVEF &gt; 50% by MUGA, echocardiogram, or other methods&#xD;
&#xD;
          -  No unstable angina&#xD;
&#xD;
          -  No unstable cardiac arrhythmia&#xD;
&#xD;
          -  No severe and/or uncontrolled hypertension&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No uncontrolled diabetes&#xD;
&#xD;
          -  No severe and/or uncontrolled infection&#xD;
&#xD;
          -  No other severe and/or uncontrolled medical condition&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  More than 6 months since prior chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No prior induction therapy for AML or myelodysplastic syndromes&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>61 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Kell, MRCPath</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital of Wales</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>North Hampshire Hospital</name>
      <address>
        <city>Basingstoke</city>
        <state>England</state>
        <zip>RG24 9NA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kent and Canterbury Hospital</name>
      <address>
        <city>Canterbury</city>
        <state>England</state>
        <zip>CT2 7NR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medway Maritime Hospital</name>
      <address>
        <city>Gillingham Kent</city>
        <state>England</state>
        <zip>ME7 5NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maidstone Hospital</name>
      <address>
        <city>Maidstone</city>
        <state>England</state>
        <zip>ME16 9QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Cornwall Hospital</name>
      <address>
        <city>Truro, Cornwall</city>
        <state>England</state>
        <zip>TR1 3LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Wales</name>
      <address>
        <city>Cardiff</city>
        <state>Wales</state>
        <zip>CF14 4XW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>July 19, 2005</study_first_submitted>
  <study_first_submitted_qc>July 19, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2005</study_first_posted>
  <last_update_submitted>September 19, 2016</last_update_submitted>
  <last_update_submitted_qc>September 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult acute monocytic leukemia (M5b)</keyword>
  <keyword>adult erythroleukemia (M6a)</keyword>
  <keyword>adult pure erythroid leukemia (M6b)</keyword>
  <keyword>adult acute megakaryoblastic leukemia (M7)</keyword>
  <keyword>adult acute myeloblastic leukemia with maturation (M2)</keyword>
  <keyword>adult acute myeloblastic leukemia without maturation (M1)</keyword>
  <keyword>adult acute myelomonocytic leukemia (M4)</keyword>
  <keyword>adult acute monoblastic leukemia (M5a)</keyword>
  <keyword>refractory anemia with excess blasts in transformation</keyword>
  <keyword>refractory anemia with excess blasts</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>untreated adult acute myeloid leukemia</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>adult acute minimally differentiated myeloid leukemia (M0)</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Anemia, Refractory, with Excess of Blasts</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
    <mesh_term>Gemtuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

